Abstract
To the Editor: In the ODYSSEY OUTCOMES trial, Schwartz et al. (Nov. 29 issue)(1) report that the proprotein convertase subtilisin-kexin type 9 (PCSK9)......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
